• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental ophthalmology >Systemic effects of topical ophthalmic beta-adrenoceptor antagonists.
【24h】

Systemic effects of topical ophthalmic beta-adrenoceptor antagonists.

机译：局部眼科β-肾上腺素受体拮抗剂的全身作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Topical ophthalmic beta-adrenoceptor antagonists (beta-blockers) are generally recognized as the treatment of choice in glaucoma management due to favourable efficacy, safety and tolerability. Despite topical ocular administration, beta-blockers are systemically absorbed, in relatively small amounts, through the nasolacrimal drainage system and can adversely affect cardiovascular and pulmonary function. While cardioselective beta-blockers, such as betaxolol, possibly confer an advantage with respect to clinical safety through their receptor affinity, systemic effects are also influenced by other pharmacological factors, including the rate and extent of systemic absorption and the extent of plasma protein binding. These factors are reviewed to distinguish the various ophthalmic beta-blockers and to explain the observed clinical differences in the safety profiles of these medications.
机译：由于良好的疗效，安全性和耐受性，局部眼用β-肾上腺素受体拮抗剂（β-受体阻滞剂）通常被认为是青光眼治疗的首选治疗方法。尽管局部经眼给药，β-受体阻滞剂通过鼻泪引流系统被系统吸收的量相对较小，并且可能对心血管和肺功能产生不利影响。虽然心脏选择性β受体阻滞剂（例如紫杉醇）可能通过其受体亲和力在临床安全性方面具有优势，但全身作用还受到其他药理学因素的影响，包括全身吸收的速率和程度以及血浆蛋白结合的程度。审查了这些因素以区分各种眼科β受体阻滞剂，并解释了这些药物安全性方面观察到的临床差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号